scholarly journals Effect of stem cell treatment on functional recovery of spinocerebellar ataxia: systematic review and meta-analysis

2021 ◽  
Vol 8 (1) ◽  
Author(s):  
Pablo Andrei Appelt ◽  
Kristin Comella ◽  
Luciane Aparecida Pascucci Sande de Souza ◽  
Gustavo José Luvizutto
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Spinocerebellar Ataxia ◽  
Functional Recovery ◽  
Rating Scale ◽  
Statistical Significance ◽  
Experimental Studies ◽  
Placebo Control ◽  
Intravenous Route ◽  
Stem Cell Treatment

Abstract Background Spinocerebellar ataxia is a hereditary neurodegenerative disease characterized by changes in balance, locomotion and motor coordination. Stem cell therapies are currently being investigated as an alternative to delay the evolution of the disease, and some experimental studies have investigated the effect of stem cell treatment on spinocerebellar ataxia. Objectives The aim of this review was to investigate whether the application of stem cells produced an effect on functional recovery in individuals with spinocerebellar ataxia. Methods The studies included in this review investigated the efficacy and safety of a protocol for the application of mesenchymal stem cells extracted from umbilical cord and adipose tissue. Two studies used intrathecal route for application and one study used intravenous route. Results Studies have shown clinical improvement in the scores of the ICARS (International Cooperative Ataxia Rating Scale), ADL (Activities of Daily Living Scale), BBS (Berg Balance Scale) and SARA (Scale for the Assessment and Rating of Ataxia), but lacked statistical significance. Conclusions There was low evidence for recommending stem cell therapy in individuals with spinocerebellar ataxia, and no statistical difference was observed for improving functional recovery of patients. Further studies are needed with different designs, largest sample sizes and placebo control, to fully understand anticipated outcomes of cellular therapy for spinocerebellar ataxia.

scholarly journals Long-Term Cryopreservation Does Not Affect Quality of Peripheral Blood Stem Cell Grafts: A Comparative Study of Native, Short-Term and Long-Term Cryopreserved Haematopoietic Stem Cells

2021 ◽  
Vol 30 ◽  
pp. 096368972110360
Author(s):  
Daniel Lysak ◽  
Michaela Brychtová ◽  
Martin Leba ◽  
Miroslava Čedíková ◽  
Daniel Georgiev ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Statistical Significance ◽  
Extended Period ◽  
High Dose ◽  
Atp Production ◽  
Cd34 Cells ◽  
Negative Effect

Cryopreserved haematopoietic progenitor cells are used to restore autologous haematopoiesis after high dose chemotherapy. Although the cells are routinely stored for a long period, concerns remain about the maximum storage time and the possible negative effect of storage on their potency. We evaluated the effect of cryopreservation on the quality of peripheral stem cell grafts stored for a short (3 months) and a long (10 years) period and we compared it to native products.The viability of CD34+ cells remained unaffected during storage, the apoptotic cells were represented up to 10% and did not differ between groups. The clonogenic activity measured by ATP production has decreased with the length of storage (ATP/cell 1.28 nM in native vs. 0.63 in long term stored products, P < 0.05). Only borderline changes without statistical significance were detected when examining mitochondrial and aldehyde dehydrogenase metabolic activity and intracellular pH, showing their good preservation during cell storage. Our experience demonstrates that cryostorage has no major negative effect on stem cell quality and potency, and therefore autologous stem cells can be stored safely for an extended period of at least 10 years. On the other hand, long term storage for 10 years and longer may lead to mild reduction of clonogenic capacity. When a sufficient dose of stem cells is infused, these changes will not have a clinical impact. However, in products stored beyond 10 years, especially when a low number of CD34+ cells is available, the quality of stem cell graft should be verified before infusion using the appropriate potency assays.

scholarly journals Preclinical efficacy of stem cell therapy for skin flap: a systematic review and meta-analysis

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Yuan Li ◽  
Qi-lin Jiang ◽  
Leanne Van der Merwe ◽  
Dong-hao Lou ◽  
Cai Lin
Keyword(s):  
Systematic Review ◽  
Stem Cells ◽  
Stem Cell ◽  
Survival Rate ◽  
Meta Analysis ◽  
Skin Flap ◽  
Cochrane Library ◽  
Skin Flaps ◽  
Cell Based Therapy ◽  
Stem Cell Treatment

Abstract Background A skin flap is one of the most critical surgical techniques for the restoration of cutaneous defects. However, the distal necrosis of the skin flap severely restricts the clinical application of flap surgery. As there is no consensus on the treatment methods to prevent distal necrosis of skin flaps, more effective and feasible interventions to prevent skin flaps from necrosis are urgently needed. Stem therapy as a potential method to improve the survival rate of skin flaps is receiving increasing attention. Methods This review followed the recommendations from the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statements. Twenty studies with 500 animals were included by searching Web of Science, EMBASE, PubMed, and Cochrane Library databases, up until October 8, 2020. Moreover, the references of the included articles were searched manually to obtain other studies. All analyses were conducted using Review Manager V.5.3 software. Results Meta-analysis of all 20 studies demonstrated stem cell treatment has significant effects on reducing necrosis of skin flap compared with the control group (SMD: 3.20, 95% CI 2.47 to 3.93). Besides, subgroup analysis showed differences in the efficacy of stem cells in improving the survival rate of skin flaps in areas of skin flap, cell type, transplant types, and method of administration of stem cells. The meta-analysis also showed that stem cell treatment had a significant effect on increasing blood vessel density (SMD: 2.96, 95% CI 2.21 to 3.72) and increasing the expression of vascular endothelial growth factor (VEGF, SMD: 4.34, 95% CI 2.48 to 6.1). Conclusions The preclinical evidence of our systematic review indicate that stem cell-based therapy is effective for promoting early angiogenesis by up regulating VEGF and ultimately improving the survival rate of skin flap. In summary, small area skin flap, the administration method of intra-arterial injection, ASCs and MSCs, and xenogenic stem cells from humans showed more effective for the survival of animal skin flaps. In general, stem cell-based therapy may be a promising method to prevent skin flap necrosis.

scholarly journals Translational Research in Stem Cell Treatment of Neuromuscular Diseases

2013 ◽  
Vol 2013 ◽  
pp. 1-17 ◽  
Author(s):  
Hakan Orbay ◽  
Hiroshi Mizuno
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Functional Integration ◽  
Neuromuscular Diseases ◽  
Pharmacological Treatments ◽  
Precursor Cell Line ◽  
Donor Cells ◽  
Significant Disability ◽  
New Treatment ◽  
Stem Cell Treatment

Neuromuscular diseases are a heterogeneous group of diseases that lead to significant disability in effected individuals. Pharmacological treatments failed to provide any significant improvement to date. Recently, the introduction of stem cells into the field of health sciences raised the hopes for a new treatment for neuromuscular diseases. In theory, stem cells, owing to their multilineage differentiation capacity, could differentiate into myofibers and neurons and replace the degenerated cells leading to recovery of the patients. Results obtained from the preclinical studies supported this theory. However, clinical trials with stem cells could not meet the expectations mainly because of early mortality, limited migration, and differentiation of the implanted cells. Modification of the stem cells before implantation, such as introduction of deficient genes or commitment to a precursor cell line provided little improvement. The biggest barrier to overcome for a successful of stem cell treatment, which also should be the focus of the future studies, is to increase the functional integration of the donor cells with the recipient tissues. Understanding the underlying pathogenic mechanisms of the neuromuscular diseases is essential to achieve this goal.

scholarly journals Neonatal derived mesenchymal stem cell mesotherapy in androgenetic alopecia: a retrospective observational study and review of literature

2015 ◽  
Vol 1 (1) ◽  
pp. 32 ◽  
Author(s):  
Leelavathy Budamakuntla ◽  
Eswari Loganathan ◽  
Shwetha Suryanarayana ◽  
Aparna Dongre
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Stem Cell ◽  
Observational Study ◽  
Ethical Issues ◽  
Dermal Papilla ◽  
External Source ◽  
Androgenetic Alopecia ◽  
Randomized Controlled Studies ◽  
Stem Cell Treatment

<p class="abstract"><strong>Background:</strong> Androgenetic alopecia has been a stressful condition for the patients and treating dermatologists alike. With the advent of stem cell therapy in various diseases, and lot of controversies and ethical issues related to it, mesenchymal stem cells MSC have passed the acid test successfully, though with many challenges. Since the stem cells in the hair follicle bulge and the dermal papilla play an important role in hair cycle and growth, introducing an external source of neonatal mesenchymal stem cells seems to be a possibility in the treatment of AGA. Aims: To know the benefits and safety of stem cell treatment in patients who underwent mesotherapy with neonatal MSC in order to establish the safety and efficacy in the treatment of AGA.</p><p class="abstract"><strong>Methods:</strong> We collected data of 40 patients treated with mesoinjections of commercially prepared neonatal MSC, with AGA of grade 2 to 7. Before and after photographs, Patient (PtGA) and Physician (PGA) Global assessment scores were used to evaluate the treatment response.</p><p class="abstract"><strong>Results:</strong> We found that 70% of the patients showed a mild response and 25% of them showed a moderate improvement in the hair growth and reduction in hair loss after 4 sittings of monthly duration. One subject showed an improvement of 72%. Patients had 6 month follow up. No major adverse events were observed.</p><p class="abstract"><strong>Conclusions:</strong> Since this is an observational study, large randomized controlled studies, with longer follow ups is recommended to make MSC therapy a novel treatment option for AGA. </p><strong>Keywords: </strong>Mesenchymal stem cells, Mesotherapy, Androgenetic alopecia

BMAC-HARVEST: Innovational Method in Osteoarticular Pathology Using Autogenous Stem Cells

2015 ◽  
Vol 638 ◽  
pp. 280-285
Author(s):  
Sólyom Árpád ◽  
Király Ildikó ◽  
Benedek Csaba ◽  
Nagy Ors ◽  
Solyom Reka ◽  
...  
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Iliac Crest ◽  
Point Of View ◽  
Daily Activities ◽  
Analog Scale ◽  
Level Of Satisfaction ◽  
Imaging Results ◽  
Imaging Point ◽  
Stem Cell Treatment

Introduction: BMAC-Harvest is an innovational method regarding autogenous stem cell treatments in various fields of medicine. In osteoarticular pathology it is used for treating chronic pathology cases as well as acute and traumatic ones. Purpose: The purpose of this study was to represent the clinical and imaging results of the patients presented to the Ist Orthopedic and Traumatology Clinic of Targu Mures. The results were obtained in the period 2012-2014 after using BMAC-Harvest autologous stem cells. Material and method: For this study the authors have included 28 patients from the Ist Orthopaedic and Traumatology Clinic of Targu Mures, suffering from different musculoskeletal pathologies. The method used on these patients was a surgical treatment, which consisted of injecting BMAC-Harvest autogenous stem cells in a unique dosage. The procedure was conducted in the operating room in sterile conditions. These cells were extracted from the iliac crest after appropriate preparation and general anesthezia. Patients were evaluated from a clinical and imaging point of view at periods of 3, 6 and 12 months after treatment. In the evaluation the following aspects were monitorized in the form of questionnaires: level of satisfaction, mobility and the daily activities of patients. The pain intensity of the patients was measured by using the VAS scale (visual analog scale). For imaging representations the authors used standard radiography and IRM in 2 occurrences and have taken into account every sign which appeared after the treatment.Results: The satisfaction level of the patients was significantly increased after the 12th month evaluation compared to results after 3rd month. The pain got considerably reduced and most of the patients could resume their activity from before the treatment. 4 patients have reported mild and medium pain 12 months after the treatment. Conclusion: Autogenous stem cell treatment is an innovational technique with satisfying results for short and medium periods. The BMAC-Harvest autogenous stem cells can be used with clear indications in locomotor organ pathology and it can help in the recuperation of the patient after a trauma. The BMAC-Harvest autogenous stem cells increase the formation of callus after a fracture or pseudoarthrosis. This is an innovational procedure and it can be used successfully in osteoarticular pathology both chronic and acute.

scholarly journals Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson’s Disease

Cells ◽  
2018 ◽  
Vol 8 (1) ◽  
pp. 14 ◽  
Author(s):  
Shin-Ichi Ueno ◽  
Shinji Saiki ◽  
Motoki Fujimaki ◽  
Haruka Takeshige-Amano ◽  
Taku Hatano ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Disease Severity ◽  
Rating Scale ◽  
Statistical Significance ◽  
Experimental Studies ◽  
Time Of Flight ◽  
Metabolome Analysis ◽  
Flight Mass Spectrometry

Although many experimental studies have shown the favorable effects of zonisamide on mitochondria using models of Parkinson’s disease (PD), the influence of zonisamide on metabolism in PD patients remains unclear. To assess metabolic status under zonisamide treatment in PD, we performed a pilot study using a comprehensive metabolome analysis. Plasma samples were collected for at least one year from 30 patients with PD: 10 without zonisamide medication and 20 with zonisamide medication. We performed comprehensive metabolome analyses of plasma with capillary electrophoresis time-of-flight mass spectrometry and liquid chromatography time-of-flight mass spectrometry. We also measured disease severity using Hoehn and Yahr (H&Y) staging and the Unified Parkinson’s Disease Rating Scale (UPDRS) motor section, and analyzed blood chemistry. In PD with zonisamide treatment, 15 long-chain acylcarnitines (LCACs) tended to be increased, of which four (AC(12:0), AC(12:1)-1, AC(16:1), and AC(16:2)) showed statistical significance. Of these, two LCACs (AC(16:1) and AC(16:2)) were also identified by partial least squares analysis. There was no association of any LCAC with age, disease severity, levodopa daily dose, or levodopa equivalent dose. Because an upregulation of LCACs implies improvement of mitochondrial β-oxidation, zonisamide might be beneficial for mitochondrial β-oxidation, which is suppressed in PD.

scholarly journals Bone Marrow-Derived Stem Cells Protect against Haloperidol-Induced Brain and Liver Damage in Mice

2018 ◽  
Vol 11 (1) ◽  
pp. 11-22 ◽  
Author(s):  
Omar M. E. Abdel-Salam ◽  
Amany A. Sleem ◽  
Eman R. Youness ◽  
Nadia A. Mohammed ◽  
Enayat A. Omara
Keyword(s):  
Nitric Oxide ◽  
Stem Cells ◽  
Bone Marrow ◽  
Stem Cell ◽  
Liver Damage ◽  
Paraoxonase 1 ◽  
High Dose ◽  
Neuronal Necrosis ◽  
Tnf Α ◽  
Stem Cell Treatment

We studied the effect of bone marrow-derived stem cells (BM-SCs) on oxidative stress, inflammation and pathological changes induced in the brain and liver of mice by the antipsychotic drug haloperidol. Mice were intraperitoneally (i.p.) treated with haloperidol at 5 mg/kg for 3 consecutive days followed by i.p. stem cell suspension and euthanized 24h later. Haloperidol resulted in increased brain and liver malondialdehyde (MDA) and nitric oxide contents together with decreased reduced glutathione (GSH). There were also decreased paraoxonase-1 (PON-1) activity in brain and liver and increased interleukin-1β (IL-1 β), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α) in brain tissue. Haloperidol produced neuronal necrosis and apoptosis and the appearance of esinophilic areas and strong TNF-α immunoreactivity in the cerebral cortex and striatum of treated mice. In the liver, centrilobular necrosis, inflammatory cell infiltration and sinusoidal haemorrhage were observed. In haloperidol-treated mice, stem cell injection had no significant effects on brain and liver levels of MDA, nitric oxide or GSH. Paraoxonase-1 activity in brain, however, decreased by stem cells application. In brain, there were decreased IL-1β, IL-6 and TNF-α. Brain neurodegenerative changes, brain TNF-immunoreactivity and histological liver damage were all markedly ameliorated after stem cell treatment. These results indicate that stem cells protect against brain and liver toxicity caused by short term haloperidol treatment in high dose. The protective effects of stem cell treatment is likely to result from interfering with cytokine release.

Sign in / Sign up

Export Citation Format

Share Document